_B_I_O_T_E_C_H_

BIOTECH · @_B_I_O_T_E_C_H_

25th Feb 2019 from TwitLonger

Who did Roche beat for $ONCE ? - Wall St weighs in:
$PFE $NVS $SGMO $BMRN $QURE $SNY $RARE
Roche's (ROG.S) $4.3 bln deal to buy Spark Therapeutics
(ONCE.O) sends the gene therapy company surging over 120 pct
premarket (nL3N20K3HT)
** WSJ reports there is at least one other bidder, which
brokerage Jefferies presumes could include ONCE's partners
Pfizer (PFE.N) and Novartis (NOVN.S)
** Novartis sells Spark's blindness treatment Luxturna
outside U.S., while Spark and Pfizer are partners on a
haemophilia B therapy
** SunTrust Robinson thinks Sanofi (SASY.PA) and Novo
Nordisk (NOVOb.CO) are the most likely suitors
** SunTrust says Pfizer, Bayer (BAYGn.DE) and Takeda
(4502.T) could have also made bids as they, along with Novo
Nordisk and Sanofi, have marketed hemophilia A drugs
** But, brokerage notes Pfizer's existing deal with Spark,
adding that Bayer is partnering with Ultragenyx (RARE.O) and
Pfizer with Sangamo (SGMO.O) on hemophilia A therapies; adds
Takeda may be "resource-restrained" after Shire acquisition
** Bernstein says Pfizer and Sanofi could have a potential
interest in Spark, and, to a lesser extent, Novartis and Takeda
** Also on Monday, Novartis exercises option to license an
RNA-targeting cardiovascular drug from Ionis Pharma (IONS.O)
(nL5N20K1ZG)
** Meanwhile, the Roche-Spark deal boosts shares of
Ultragenyx, Sangamo and other gene therapy specialists between 4
pct and 21 pct

Reply · Report Post